R. P. Pazo Cid

Desmoid-Type Fibromatosis: Who, When, and How to Treat

J. Hernando Cubero, J. Martínez Trufero, I. Pajares Bernad, 2017, Current Treatment Options in Oncology.

Doxorubicin plus sorafenib in treatment of advanced hepatocellular carcinoma.

R. P. Pazo Cid, J. Lao, M. Lanzuela, 2011, JAMA.

Delphi consensus on strategies in the management of opioid-induced constipation in cancer patients

J. Porta-Sales, M. Escapa, L. Visa, 2019, BMC Palliative Care.

Advanced HER2-positive gastric cancer: current and future targeted therapies.

A. Antón, R. P. Pazo Cid, R. Pazo Cid, 2013, Critical reviews in oncology/hematology.

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kazuhiro Yoshida, A. Benson, Y. Bang, 2018, The Lancet.

Phase II LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC).

P. Philip, J. Lacy, P. Hammel, 2018 .

Activity of weekly paclitaxel−cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors

A. Antón, I. Bernad, J. M. Trufero, 2017, Clinical and Translational Oncology.

Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma (NCT03665441).

O. Bouché, L. Mineur, J. Metges, 2022, Journal of Clinical Oncology.